Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CASP7 | P55210 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334311 | 0.84 | NPC1 (0.42) | ALDH1A1KDM4EHPGDCASP1GAA | |
| SCHEMBL15922141 | 0.79 | F9 (0.43) | ALDH1A1KDM4EHPGDCASP1GAA | |
| SCHEMBL4399692 | 0.79 | CHRNB2 (0.45) | ALDH1A1KDM4EHPGDGAAGRM4 | |
| SCHEMBL18805037 | 0.76 | BRD4 (0.48) | GRM4CHRNB2CHRNA4ESR1ESR2 | |
| SCHEMBL1121898 | 0.76 | BRD4 (0.48) | GRM4CHRNB2CHRNA4ESR1ESR2 | |
| SCHEMBL10222158 | 0.76 | ALDH1A1 (0.49) | ALDH1A1GRM4CHRNB2CHRNA4KMT2A | |
| SCHEMBL745847 | 0.76 | ESR1 (0.62) | ALDH1A1KDM4EHSD17B10MAPTESR1 | |
| SCHEMBL18788867 | 0.76 | CHRNB2 (0.42) | GRM4CHRNB2CHRNA4ESR1ESR2 | |
| SCHEMBL1530408 | 0.76 | BRD4 (0.45) | ALDH1A1KDM4EHPGDGRM4CHRNB2 | |
| SCHEMBL29673224 | 0.76 | CHRNB2 (0.40) | CA12CA1CA9GRM4CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | claimed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| EP-3596067-B1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-06-07 | — | — | EP | disclosed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | disclosed |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-26 | — | — | US | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |
| US-20200131157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2020-04-30 | — | — | US | disclosed |
| WO-2018167695-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-09-20 | — | — | WO | disclosed |
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEXA THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | PITZER, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | PITZER, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-2032565-A2 | BENZISOXAZOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pfizer Products Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1948659-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007088438-A2 | BENZISOXAZOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | ALDH1A1 1738/4885KDM4E 4688/4885HPGD 611/4885 |
| US-20150344447-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6D, PDE6A | ALDH1A1 1526/4885KDM4E 4010/4885HPGD 1053/4885 |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | BMI1, MLLT1, EED | ALDH1A1 2583/4885KDM4E 107/4885HPGD 2773/4885 |
| US-20090221655-A1 | ANTIBACTERIAL AGENTS | OXSR1, CBR3, AOC3 | ALDH1A1 2683/4885KDM4E 4079/4885HPGD 2452/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | ALDH1A1 1738/4885KDM4E 4688/4885HPGD 611/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | ALDH1A1 1717/4885KDM4E 4681/4885HPGD 617/4885 |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | ALDH1A1 2840/4885KDM4E 136/4885HPGD 3118/4885 |
| US-20200131157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC3 | ALDH1A1 1717/4885KDM4E 4681/4885HPGD 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.